Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Axsm save search
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12 narcolepsy symphony trial therapeutics
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
Published: 2023-10-24 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 1.98%
H: 2.15%
C: 0.76%
axs-05 conference disease alzheimer’s trials trial therapeutics results
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Published: 2023-07-07 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.69%
H: 0.07%
C: -2.31%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder
Published: 2022-12-07 (Crawled : 13:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.32%
H: 4.77%
C: 3.52%
auvelity trial therapeutics major depressive disorder
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
Published: 2022-12-07 (Crawled : 12:20) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.32%
H: 4.77%
C: 3.52%
auvelity meeting trial therapeutics major depressive disorder
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
Published: 2022-11-28 (Crawled : 12:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 25.02%
H: 12.17%
C: 5.22%
axs-05 disease trial therapeutics alzheimer’s
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial
Published: 2022-10-03 (Crawled : 12:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 2.08%
H: 1.19%
C: -0.48%
sunosi trial therapeutics solriamfetol
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
Published: 2022-10-03 (Crawled : 11:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 2.08%
H: 1.19%
C: -0.48%
sunosi trial therapeutics solriamfetol
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
Published: 2022-06-02 (Crawled : 19:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: -2.12%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical PsychiatryAXS-05
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Published: 2022-05-31 (Crawled : 12:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
Published: 2022-05-18 (Crawled : 12:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 4.9%
H: 3.4%
C: -4.3%
axs-05 trial therapeutics publication phase 2 major depressive disorder
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
Published: 2021-09-16 (Crawled : 11:20) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: -0.32%
H: 6.3%
C: 3.26%
narcolepsy phase 3 trial
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
Published: 2021-08-09 (Crawled : 12:00) - biospace.com/
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: -34.96%
H: 6.06%
C: -17.06%
treatment phase 2 depression trial
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
Published: 2020-12-31 (Crawled : 12:00) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 1.25%
H: 0.51%
C: -3.36%
disease alzheimer phase 3 trial alzheimer’s alzheimer's disease alzheimer's
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
Published: 2020-12-31 (Crawled : 11:03) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 1.25%
H: 0.51%
C: -3.36%
positive phase 3 results trial treatment
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
Published: 2020-12-08 (Crawled : 11:02) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 4.18%
H: 0.33%
C: -1.87%
positive results positive results trial depression major depressive disorder
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
Published: 2020-12-02 (Crawled : 11:01) - globenewswire.com
AXSM | $71.23 -2.53% -2.6% 580K
|
Health Technology
|
| O: 0.66%
H: 3.28%
C: 2.84%
positive results depression positive results trial treatment
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.